Katrin Milger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katrin Milger has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Carlo Mümmler
Department of Medicine V LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL) Munich Germany
2 shared publications Alexandra Lenoir
Department of Medicine V, LMU University Hospital, Comprehensive Pneumology Center (CPC), LMU Munich, Member of the German Center of Lung Research (DZL), Munich, Germany
1 shared publication- Alexandra Lenoir
Department of Medicine V, LMU University Hospital, Comprehensive Pneumology Center, LMU Munich, Member of the German Center for Lung Research (DZL), Munich, Germany
1 shared publication - Andrea Waelde
Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany
1 shared publication Carmen Pizarro
Department of Internal Medicine II, Cardiology, Pneumology, Angiology, University Hospital Bonn, Bonn, Germany
1 shared publication- Claus Neurohr
Department of Pulmonology and Respiratory Medicine, Robert-Bosch-Hospital, 70376 Stuttgart, Germany
1 shared publication
Latest Publications
- 3 April 2026
- Published by Elsevier in The Lancet
- Vol. 407 (10536) , 1330-1331
Clinical phenotyping improves choices of biologics in asthma
- 3 April 2026
- Published by Elsevier in The Lancet
- Vol. 407 (10536) , 1330-1331
Clinical phenotyping improves choices of biologics in asthma
- Open Access
- 8 July 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 4 (4) , 100533
Long-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study
- 8 July 2025
- Published by Elsevier in Journal of Allergy and Clinical Immunology: Global
- Vol. 4 (4) , 100533
Open AccessLong-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study
- Open Access
- 9 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1120
Current Blood Eosinophilia Does Not Predict the Presence of Pulmonary Hypertension in Patients with End-Stage Lung Disease
Objectives: To investigate the role of blood eosinophils in predicting PH in end-stage lung disease. Methods: We conducted a retrospective study of adults with CF, COPD, and ILD who underwent RHC during lung transplant evaluations (2010–2022). Patients were classified by the 2022 ECS/ERS PH guidelines with pulmonary function and laboratory tests, including hemograms. The eosinophil threshold was set at 0.30 G/L. Results: We analyzed 663 patients (n = 89 CF, n = 294 COPD, and n = 280 ILD). Severe PH was more common in ILD (16%) than in CF (4%) and COPD (7%) (p = 0.0002), with higher eosinophil levels in ILD (p = 0.0002). No significant correlation was found between eosinophil levels and hemodynamic parameters (PAPm, PVR, and CI) across CF, COPD, and ILD (PAPm: p = 0.3974, p = 0.4400 and p = 0.2757, respectively; PVR: p = 0.6966, p = 0.1489 and p = 0.1630, respectively; CI: p = 0.9474, p = 0.5705 and p = 0.5945, respectively), nor was a correlation observed in patients not receiving OCS. Linear regression analysis confirmed the lack of association (PAPm: p = 0.3355, p = 0.8552 and p = 0.4146, respectively; PVR: p = 0.6924, p = 0.8935 and p = 0.5459, respectively; CI: p = 0.4260, p = 0.9289 and p = 0.5364, respectively), controlling for 6-MWD, Nt-proBNP, and ICS/OCS dosages. ROC analysis indicated eosinophils were ineffective in distinguishing PH severity levels across these diseases (AUC 0.54, 0.51, and 0.53, respectively). The analysis of eosinophil levels measured 18 ± 6 months prior to baseline found no predictive correlation with the presence of PH either. Eosinophil levels did not differ significantly among PH groups, but eosinophilic COPD was linked to more unclassified PH, higher CO, and greater lung volumes than non-eosinophilic COPD. Conclusions: In our cohort of end-stage CF, COPD, and ILD patients, blood eosinophilia did not predict the presence of PH but was associated with hemodynamic parameters and lung volumes in COPD.
- 9 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1120
Open AccessCurrent Blood Eosinophilia Does Not Predict the Presence of Pulmonary Hypertension in Patients with End-Stage Lung Disease
Objectives: To investigate the role of blood eosinophils in predicting PH in end-stage lung disease. Methods: We conducted a retrospective study of adults with CF, COPD, and ILD who underwent RHC during lung transplant evaluations (2010–2022). Patients were classified by the 2022 ECS/ERS PH guidelines with pulmonary function and laboratory tests, including hemograms. The eosinophil threshold was set at 0.30 G/L. Results: We analyzed 663 patients (n = 89 CF, n = 294 COPD, and n = 280 ILD). Severe PH was more common in ILD (16%) than in CF (4%) and COPD (7%) (p = 0.0002), with higher eosinophil levels in ILD (p = 0.0002). No significant correlation was found between eosinophil levels and hemodynamic parameters (PAPm, PVR, and CI) across CF, COPD, and ILD (PAPm: p = 0.3974, p = 0.4400 and p = 0.2757, respectively; PVR: p = 0.6966, p = 0.1489 and p = 0.1630, respectively; CI: p = 0.9474, p = 0.5705 and p = 0.5945, respectively), nor was a correlation observed in patients not receiving OCS. Linear regression analysis confirmed the lack of association (PAPm: p = 0.3355, p = 0.8552 and p = 0.4146, respectively; PVR: p = 0.6924, p = 0.8935 and p = 0.5459, respectively; CI: p = 0.4260, p = 0.9289 and p = 0.5364, respectively), controlling for 6-MWD, Nt-proBNP, and ICS/OCS dosages. ROC analysis indicated eosinophils were ineffective in distinguishing PH severity levels across these diseases (AUC 0.54, 0.51, and 0.53, respectively). The analysis of eosinophil levels measured 18 ± 6 months prior to baseline found no predictive correlation with the presence of PH either. Eosinophil levels did not differ significantly among PH groups, but eosinophilic COPD was linked to more unclassified PH, higher CO, and greater lung volumes than non-eosinophilic COPD. Conclusions: In our cohort of end-stage CF, COPD, and ILD patients, blood eosinophilia did not predict the presence of PH but was associated with hemodynamic parameters and lung volumes in COPD.